Skip to Content
 

VICC toll-free number 1-877-936-8422

Urologic / Genitourinary Cancers

The Urologic Oncology Program offers an integrated, comprehensive, multidisciplinary approach to the treatment of all genitourinary malignancies, with a special emphasis on providing patients with innovative therapies derived from cutting-edge basic research.

Clinical Trials for Urologic / Genitourinary Cancers

32 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

Bladder

VICCURO1322

03/28/2014

Vanderbilt Assessment of Shed ALCAM in Urogenital Cancers (VanSA)

Diagnostic

Prostate

VICCURO15140

01/18/2016

Analysis of Cell-Free DNA (cfDNA) in Men with Elevated PSA Levels

Health Services Research

Prostate

VICCURO1589

03/16/2016

A Prospective Observational Cohort Study of Patients with Castration- Resistant Prostate Cancer (CRPC) in the United States

Other

Prostate

VICCURO1734

05/02/2017

Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study

Other

Bladder

VICCURO1717

04/06/2017

Multi-Institutional Study to Evaluate DNA Methylation Markers for Detection of Primary Bladder Cancers in Urine Samples from a Cohort of Patients with Hematuria

Other

Prostate

VICCURO16112

10/25/2016

Prospective Observational Trial of an Absorbable Hydrogel Spacer in Prostate Cancer Radiotherapy

Other

Bladder
Urologic

VICCURO15108

05/31/2016

Urinary Biomarkers in the Detection of Transitional Cell Carcinoma of the Bladder

Other

Bladder

VICCURO1618

05/24/2016

Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma A Multicenter, Prospective Blinded Pivotal Study

Other

Prostate

URO70807-M

05/10/2012

Men's Eating and Living Study: A Randomized trial of diet to alter disease progression in prostste cancer patients on active surveillance

Supportive Care

Prostate

VICCURO16133

03/31/2017

Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer

Treatment

Bladder
Urologic
Uterine

VICCURO16119

02/21/2018

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Treatment

Prostate

VICCURO1782

01/09/2018

A Randomized Phase 2 Study of Cediranib in Combination with Olaparib versus Olaparib Alone in Men with Metastatic Castration Resistant Prostate Cancer

Treatment

Kidney (Renal Cell)

VICCURO16135

11/15/2017

A Phase II Study of the Efficacy and Safety of Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer after Treatment with PD-1 or PD-L1 Inhibitors

Treatment

Prostate

VICCURO1626

09/25/2017

A Phase Ib, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination with Radium-223 Dichloride in Patients with Castrate-Resistant Prostate Cancer who have Progressed Following Treatment with an Androgen Pathway Inhibitor

Treatment

Bladder
Kidney (Renal Cell)
Uterine

VICCURO16158

09/07/2017

A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (ANTI−PD-L1 Antibody) as Monotherapy and in Combination with Platinum-Based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Treatment

Bladder

VICCURO1723

08/10/2017

An Open Label, Multicenter, Single Arm Phase II Pilot Study to Evaluate the Efficacy and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract whose Tumors Harbor a TSC1 and/or a TSC2 Mutation

Treatment

Kidney (Renal Cell)
Melanoma

VICCURO16101

08/10/2017

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Treatment

Urologic

VICCURO1724

07/10/2017

A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma

Treatment

Kidney (Renal Cell)

ECOGUROEA8143

06/09/2017

PHIII Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy.

Treatment

Kidney (Renal Cell)

VICCURO16120

05/15/2017

A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti−PD-L1 Antibody) As Adjuvant Therapy In Patients With Renal Cell Carcinoma At High Risk Of Developing Metastasis Following Nephrectomy

Treatment

Urologic

VICCURO1668

01/11/2017

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

Treatment

Kidney (Renal Cell)
Lung
Melanoma
Miscellaneous
Non Small Cell
Ovarian
Uterine

VICCPHI1676

11/04/2016

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects with Advanced or Metastatic Solid Tumors

Treatment

Kidney (Renal Cell)
Lung
Melanoma
Miscellaneous
Non Small Cell
Uterine

VICCPHI1634

08/30/2016

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects with Advanced or Metastatic Solid Tumors

Treatment

Prostate

VICCURO1677

08/09/2016

Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients with Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study

Treatment

Bladder
Colon
Gastric/Gastroesophageal
Kidney (Renal Cell)
Rectal
Urologic

VICCGI15126

05/03/2016

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

Treatment

Prostate

NRGUROR0924

03/10/2016

Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Treatment

Bladder
Breast
Hematologic
Leukemia
Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Pancreatic
Urologic

VICCHEMP1558

10/09/2015

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Treatment

Prostate

VICCURO1540

07/08/2015

A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men with High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy. MDV3100-13

Treatment

Prostate

CTSUALLIANCEURO031201-M

11/21/2014

URO A031201: Phase III Trial of Enzalutamide (NSC # 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

Treatment

Bladder
Colon
Esophageal
Gastric/Gastroesophageal
Neuro-Oncology
Ovarian
Urologic
Uterine

VICCMD1403

06/02/2014

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Treatment

Prostate

CTSUUROS1216-M

01/16/2014

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

Treatment

Prostate

CTSUUROC90203-M

11/05/2007

A randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer